Misdiagnosis of bipolar disorder

American Journal of Managed Care

Volumn 11, Issue SUPPL. 9, 2005, Pages

  Perlis, Roy H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; DESIPRAMINE; LITHIUM; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ANAMNESIS; ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HEALTH SURVEY; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MOOD DISORDER; OUTCOMES RESEARCH; PANIC; PATIENT INFORMATION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RELIABILITY; REVIEW; RISK ASSESSMENT; SUBSTANCE ABUSE; SUICIDE ATTEMPT; SYMPTOM; TREATMENT FAILURE; UNEMPLOYMENT;

BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; EPISODE OF CARE; HUMANS; MOOD DISORDERS; QUALITY OF HEALTH CARE; RECURRENCE;

EID: 27544509429     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.
2. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-850.
3. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry. 2001;61 (suppl 13):38-41.
4. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161-174.
5. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994;31:281-294.
6. Morselli PL, Elgie R; GAMIAN Europe. GAMIAN-Europe/BEAM survey I-global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders. Bipolar Disord. 2003;5:265-278.
7. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003;5:421-433.
8. Post RM, Leverich GS, Nolen WA, et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord. 2003;5:396-406.
9. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152:1130-1138.
10. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry. 1979;36:555-559.
11. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290:1467-1473.
12. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161:2222-2229.
13. Baethge C, Baldessarini RJ, Khalsa HM, Hennen J, Salvatore P, Tohen M. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry. 2005;162:1008-1010.
14. Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry. 2001;158:1265-1270.
15. Perlis RH, Miyahara S, Marangell LB, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2004;55:875-881.
16. Baldassano CF. Assessment tools for screening and monitoring bipolar disorder. Bipolar Disord. 2005;7 (suppl)1:8-15.
17. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003;64:53-59.
18. Hirschfeld RM, Holzer C, Calabrese JR, et al. Validity of the mood disorder questionnaire: a general population study. Am J Psychiatry. 2003;160:178-180.
19. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157:1873-1875.
20. Simpson SG, McMahon FJ, McInnis MG, et al. Diagnostic reliability of bipolar II disorder. Arch Gen Psychiatry. 2002;59:736-740.
21. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol. 2003;23(3 suppl 1):S21-S26.
22. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22:379-387.
23. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151:1372-1374.
24. Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2001;23:92-95.